NK NantKwest Inc.

1.5
-0.03  -2%
Previous Close 1.53
Open 1.53
Price To Book 1.09
Market Cap 147,550,776
Shares 98,367,184
Volume 470,915
Short Ratio
Av. Daily Volume 167,497
Stock charts supplied by TradingView

NewsSee all news

  1. NantKwest Announces Phase 1 Results for First-in-Human PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) in Patients with Locally Advanced or Metastatic Solid Cancers

    First-in-human trial shows no dose-limiting toxicities in six subjects treated as out-patients with PD-L1.t-haNK off-the-shelf CAR NK cell therapy with potential to overcome limitations of CAR-T therapies for solid

  2. NantKwest Hosting Key Opinion Leader Meeting on Novel Immunotherapeutic Approaches to Address the Unmet Medical Needs of Patients with Merkel Cell Carcinoma, Triple-Negative Breast Cancer and Solid Tumors

    NantKwest, Inc. (NASDAQ:NK), a next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and

  3. NantKwest Announces Presentation of Positive Phase 2 Clinical Data of Natural Killer Cell Therapy in Metastatic Merkel Cell Carcinoma at SITC 2019

    Durable Responses Demonstrated in 2 of 7 Patients with Refractory Metastatic MCC Data Supportive of Planned Off-the-Shelf Clinical Trial to Confirm Activity and Safety NantKwest Inc. (NASDAQ:NK), a next generation,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

90% Disease Control with Median Overall Survival of 9.5 Months - noted - November 7, 2018.
haNK
Pancreatic cancer vaccine
Phase 1/2 ongoing.
haNK
Pancreatic cancer vaccine
80% Disease Control noted - November 7, 2018.
haNK
Triple Negative Breast Cancer (TNBC)
First dosing announced October, 2017.
haNK
Solid tumors
Phase 2 ongoing.
aNK
Merkel cell carcinoma
Phase 2 data noted 2/7 responses (1 PR / 1 CR) - November 7, 2019.
haNK + avelumab + N-803
Merkel cell carcinoma (MCC)
Phase 1b abstract at ASCO noted 2/8 SAEs.
haNK + other vaccines (NANT vaccine) (ASCO 2019)
Triple Negative Breast Cancer
IND clearance announced June 5, 2019.
CD19-t-haNK
B-cell lymphoma
Phase 1b data at ASCO 2019 - ORR of 58%, CR rate of 33%.
Nanatinostat (VRx-3996) and valganciclovir
Epstein-Barr Virus Associated Lymphoma
Phase 1 preliminary data released December 2, 2019.
PD-L1 t-haNK
Solid tumors

Latest News

  1. NantKwest Announces Phase 1 Results for First-in-Human PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) in Patients with Locally Advanced or Metastatic Solid Cancers

    First-in-human trial shows no dose-limiting toxicities in six subjects treated as out-patients with PD-L1.t-haNK off-the-shelf CAR NK cell therapy with potential to overcome limitations of CAR-T therapies for solid

  2. NantKwest Hosting Key Opinion Leader Meeting on Novel Immunotherapeutic Approaches to Address the Unmet Medical Needs of Patients with Merkel Cell Carcinoma, Triple-Negative Breast Cancer and Solid Tumors

    NantKwest, Inc. (NASDAQ:NK), a next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and

  3. NantKwest Announces Presentation of Positive Phase 2 Clinical Data of Natural Killer Cell Therapy in Metastatic Merkel Cell Carcinoma at SITC 2019

    Durable Responses Demonstrated in 2 of 7 Patients with Refractory Metastatic MCC Data Supportive of Planned Off-the-Shelf Clinical Trial to Confirm Activity and Safety NantKwest Inc. (NASDAQ:NK), a next generation,